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Abstract
Introduction
▪ Cannabis, cannabinoids and medical marijuana all encompass a topic 
that is highly controversial, as well as lacking in scientifically based 
evidence for chronic pain therapy. To date, the Food and Drug 
Administration (FDA) has approved three different cannabinoid based 
products that are currently being used for various medical issues, such 
as Dronabinol (Marinol and Syndros) and Nabilone (Cesamet). 
▪ Limited amounts of research have been conducted due to the Drug 
Enforcement Administrations (DEA) schedule of cannabis as a 
Schedule I drug.
▪ Chronic pain is also a highly discussed topic due to the difficult nature 
of finding proper therapy to improve overall quality of life. Patients 
who deal with chronic pain are often left with prescription opiates for 
pain management, all of which have adverse effects. Authors 
Feingold, Goor-Aryeh, Bril, Delayahu, and Lev-Ran (2017) state 
long-term treatment with opioids may be complicated due to tolerance 
and addiction, which may not be adequately managed and potentially 
worsen the pain. 
▪ An in-depth evaluation of the adverse reactions, addictive effects, as 
well as clinical and statistical significance will be examined in those 
who choose to try cannabinoid products for chronic pain therapy.
Research Questions
Literature Review




▪ Medical Cannabis vs Opiate Efficacy 
▪ Goldenberg, Reid, IsHak, and Danovitch (2017) found cannabis 
use for increased health-related quality of life (HRQoL) had vague 
results and most effects were non-significant or nearing zero. Some 
reports showed a mild benefit in some pain conditions while in 
others there was a decrease in HRQoL.
▪ Narang, Gibson, Wasan, Ross, Michna, Nedeljkovic, and Jamison 
(2008) conducted two phases and found Dronabinol in Phase I had 
significant pain relief after 8 hours per the total pain relief at 8 
hours score (TOTPAR), (20 mg vs placebo at p < .01, 10 mg vs 
placebo at p < .05). For adjuvant therapy in Phase II, dronabinol 
proved to have a significant effect in lowering pain from baseline 
(p < .001), decreasing pain bothersomeness, as well as increased 
satisfaction in their therapy (p < .01).
▪ Boehnke, Litinas, and Clauw (2016) evaluated the efficacy of 
medical cannabis compared to opiates in chronic pain patients. 
Figure II highlights the changes before and after cannabis use. 
▪ In 1996, the state of California was the first in the union to allow for 
the use of medical marijuana. Since then, 28 more states have enacted 
similar laws (National Conference of State Legislatures, [NCSL], 
2017).
▪ As of 2014, the CDC reported opioid deaths were up 369%, which is 
more than 91 deaths per day from overdose (Centers for Disease 
Control, [CDC], 2017). The purpose of this study is to compare 
medical marijuana to opiates in safety and addiction; in addition, the 
efficacy of using cannabis as an alternative for individuals who deal 
with chronic pain will be investigated. 
▪ A literature review was conducted to find systematic reviews, meta-
analyses and randomized controlled trials (RCTs) that evaluated 
medical marijuana and opiates for the treatment of chronic pain. 
▪ Four databases were surveyed with multiple sources found in 
CINAHL, Cochrane Database, PubMed and PsycINFO. 
▪ Current literature shows that cannabinoids may provide potential 
benefit with short-term use, but not without possible adverse effects. 
With the current lack of research on long-term treatment of chronic 
pain with cannabinoids, additional research needs to be conducted to 
further understand the potential adverse effects associated with 
cannabinoid use.
▪ Keywords: adverse effects, cannabinoid addiction, cannabinoids, 
chronic pain, efficacy, medical marijuana, pain management.
▪ Is medical cannabis safe to use for chronic pain? What are the 
documented adverse effects associated with using this medication?
▪ How addictive is medical cannabis compared to other addictive 
substances? What addictive qualities are associated with starting this 
medication?
▪ What has been shown to be more effective in the treatment of chronic 
pain, medical cannabis or opiates?
▪ Cannabinoids for Chronic Pain- Safety and Adverse Events
▪ Whiting et al. (2015) found in eight of the 28 studies, patients 
who reported at least 30% decrease in pain were those who used 
cannabinoids rather than those who used a placebo (OR = 1.41; 
95% CI =0.99-2.00).  They also found common adverse events 
that included dizziness, dry mouth, nausea, fatigue, 
hallucinations, drowsiness and confusion.
▪ Results found by Ware, Wang, Shapiro, and Collet (2015), 
showed medical cannabis users were at increased risk of non-
serious adverse events, 818, ranging from mild to moderate 
events such as: headache, nasopharyngitis, nausea, somnolence, 
and dizziness compared to the 581 events documented in the 
control (IRR = 1.64, 95% CI = 1.35-1.99). Overall, individuals in 
the medical cannabis group experienced better pain control than 
the control (change = .92; 95% CI = .62-1.23) vs (change = .18; 
95% CI = -.13).
▪ Nugent et al. (2017) found no detection of significant differences 
between the cannabis group compared to the control group when 
it came to serious adverse events (IRR = 1.08; 95% CI = 0.57-
2.04). This study did evaluate long-term effects associated with 
cannabis use and found it to be associated with cannabinoid 
hyperemesis syndrome as well as incident cannabis use disorder 
(OR = 9.5; 95% CI = 6.4-14.1)
▪ Comparison of Addictive Substances to Cannabinoids
▪ Feingold, Goor-Aryeh, Bril, Delayahu, and Lev-Ran (2017) 
studied whether or not these patients were more apt to abuse 
opioids or medical cannabis. Figure I shows the results.
▪ Richter, Pugh, Smith, and Ball (2016) examined alcohol, 
marijuana, as well as other illicit drugs and prescription drugs as 
possible correlates to nicotine product use. Results revealed any 
form of nicotine use, co-occurring use with other substances was 
documented (79.4% alcohol (OR = 11.5; 95% CI = 8.4- 15.7), 
59.7% marijuana (OR = 12.7%; 95% CI = 9.5- 16.8), 53.9% 
poly-substance use (OR = 15.5; 95% CI = 11.4- 21.0), 18.8% 
prescription drugs (OR = 8.3; 95% CI = 5.4- 12.8), 8.5% other 
illicit drugs (OR = 19.1; 95% CI = 9.0- 40.6).
▪ It is difficult to find effective treatments for chronic pain, but having 
multiple therapy modalities increases the likelihood of controlling pain
▪ Alternative therapies will aid in alleviating the current opiate epidemic
▪ Medical cannabis has also been shown to be effective for other 
diseases such as fibromyalgia, neuropathy, multiple sclerosis, cystic 
fibrosis, migraines and gastrointestinal conditions
▪ Medical cannabis is associated with reduced risk of addiction, lessened 
side effects and a possible decrease in other pain medications 
compared to opiates
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Statement of the Problem
▪ According to Boehnke, Litinas, and Clauw (2016), opiates are one of 
the most commonly used medications to treat chronic pain. With that 
notion, opiates are also ineffective for many types of pain as well as 
associated with addictive and significant morbidity and mortality 
rates. 
▪ With the ever-growing opiate epidemic, an alternative treatment 
modality would be of great benefit. Cannabinoid therapy could be a 
potential secondary option rather than continued opiate therapy if 
research supports the advocacy and safety.
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Literature Review Cont.
▪ The National Institutes of Health (NIH) has supported around 281 
projects totaling over $111 million on cannabinoid research, 49 
projects ($21 million) examined therapeutic properties of 
cannabinoids, and 15 projects ($9 million) focused on (CBD)
▪ Medical cannabis has multiple adverse events similar to other drugs
▪ Medical cannabis has been found to be less addictive and problematic 
than opiates according to the literature review, reference the pie chart
▪ Medical cannabis has been shown to improve overall HRQoL and 
reduce medication need, not always statistically but clinically 
▪ More research is needed to understand the long term effects as well as 
short term outcomes in larger populations
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